Generali Investments Towarzystwo Funduszy Inwestycyjnych Has $723,000 Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 77.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,000 shares of the company's stock after purchasing an additional 27,000 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych owned approximately 0.06% of Intellia Therapeutics worth $723,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Whipplewood Advisors LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after buying an additional 794 shares during the period. KBC Group NV boosted its stake in shares of Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after buying an additional 1,020 shares during the period. Point72 DIFC Ltd acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $151,000. Finally, AdvisorNet Financial Inc increased its stake in Intellia Therapeutics by 96.4% during the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock worth $118,000 after acquiring an additional 4,950 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NTLA. Canaccord Genuity Group reiterated a "buy" rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group reaffirmed a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday. Barclays decreased their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday. BMO Capital Markets cut their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a report on Friday, January 10th. Finally, Oppenheimer reduced their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $42.12.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 29,000 shares of company stock valued at $352,551 in the last ninety days. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA traded down $0.64 during midday trading on Monday, hitting $9.45. 2,996,569 shares of the stock were exchanged, compared to its average volume of 3,289,607. The business's 50-day moving average price is $10.85 and its 200 day moving average price is $15.55. Intellia Therapeutics, Inc. has a 12 month low of $8.96 and a 12 month high of $33.28. The stock has a market capitalization of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.